Jasper Therapeutics Inc (JSPR) — Institutional Investor Activity (Q2 2026)

AI summary pending

AI summary pending

AI summary pending

In this 8-K, Jasper Therapeutics confirmed that July 16, 2026 — the closing date of its acquisition of Kira Pharmaceuticals — is the record date for determining stockholders entitled to receive contingent value rights (CVRs). Each share of common stock held as of that date gets one CVR, and holders would share a $30.0 million milestone payment if the FDA issues a Priority Review Voucher tied to briquilimab on or before December 31, 2028. The CVRs can't be transferred except in limited cases and won't be listed or registered for trading. This filing mainly formalizes previously disclosed terms; it doesn't say whether the milestone will actually happen.

Jasper Therapeutics acquired Kira Pharmaceuticals via a merger on July 16, 2026. Jasper issued about 5.2 million common shares and 4.6 million convertible preferred shares to Kira shareholders. After the merger and a related financing, pre-merger Jasper stockholders will hold roughly 6.7% of the company, former Kira stockholders about 49.9%, and new investors about 43.5%. The company also appointed Patrick Crutcher to the board, subject to stockholder ratification.

Jasper Therapeutics announced it has completed the acquisition of Kira Pharmaceuticals, a company developing complement therapies for immune-mediated diseases, in an all-stock deal. The company also entered into a securities purchase agreement for a private placement financing that will raise $132 million. These disclosures were made in a press release furnished with the SEC.